— Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share expected.
— Total product revenue grew by 9.1% to $16.8 million versus $20.57 million expected.
— The bottom line reflected the evolution of the commercial strategy and the company’s focus on both operational productivity and expense management.
— The company reported growth in net product sales and net revenue per pack for its two core commercial attention deficit hyperactivity disorder (ADHD) products, Adzenys XR-ODT and Cotempla XR-ODT.
— During the fourth quarter of 2019, the company substantially expanded the number of participating pharmacies in the Neos RxConnect network to about 500 pharmacies, including one regional pharmacy chain, as of December 31, 2019.
— Neos recently agreed with a third-party to commercialize Neos’ ADHD portfolio in Puerto Rico. The commercial launch is anticipated to occur in the second quarter of 2020.
— The company achieved top-line results from the NT0502 Phase 1 pilot pharmacokinetic study and plans to initiate an ascending dose study in the second half of the year. This underserves patients struggling with chronic sialorrhea, otherwise known as excessive drooling, across numerous debilitating CNS disorders.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on